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Abstract
Introduction: At present, there is neither a laboratory test nor an imaging technique able to differentiate people
with fibromyalgia (FM) from healthy controls. This lack of an objective biomarker has hampered FM recognition
and research. Heart rate variability (HRV) analyses provide a quantitative marker of autonomic nervous system
activity. Nighttime is a stable period in which most people are resting. Sleep is modulated by autonomic activity.
Sleeping problems are prominent in FM. The objectives of this study are: 1) to explore different nocturnal HRV
parameters as potential FM biomarkers and 2) to seek correlation between such HRV parameters and diverse FM
symptoms.
Methods: We studied 22 women suffering from FM and 22 age-matched controls. All participants filled out several
questionnaires related to FM symptoms. All participants used a Holter monitor over 24 hours while undertaking
their routine activities during the day and while sleeping at their homes at night. Time-domain HRV parameters
analyzed from 0000 to 0600 hours included, among others: mean normal-normal interbeat intervals (mean NN),
standard deviation of the NN intervals (SDNN), and standard deviation of the successive NN differences (SDSD).
Results: Nocturnal SDNN of less than 114 ms had the greatest predictive value to set apart patients from controls
with an odds ratio of 13.6 (95% confidence interval: 3.9 to 47.8). In patients, decreased nighttime HRV markers
indicative of sympathetic predominance had significant correlations with several FM symptoms: SDSD was
associated with pain intensity (r = - 0.65, P = 0.001). SDNN correlated with constipation (r = - 0.53, P = 0.001), and
mean NN with depression (r = - 0.53, P = 0.001). Controls displayed an opposite behavior. For them, increased
nighttime SDNN correlated with Fibromyalgia Impact Questionnaire scores (r = 0.69, P = 0.001) and with other FM
symptoms.
Conclusions: Nocturnal HRV indices indicative of sympathetic predominance are significantly different in FM
women when compared to healthy individuals. In FM patients, these HRV parameters correlated with several
symptoms including pain severity. Opposite associations were seen in controls. FM may not be just one end of a
continuous spectrum of common symptoms. Nocturnal HRV analyses are potential FM biomarkers.
Introduction
Fibromyalgia is a common controversial illness with pre-
valence in the general population ranging from 3 to 5%.
The overwhelming majority of affected individuals are
women. Patients who suffer from FM often have multi-
ple complaints related to pain, sleep, fatigue, anxiety,
and depression [1]. Some investigators conceive FM as
just one end of a continuous spectrum of ‘normal’
symptoms [2]. Thus the label ‘fibromyalgianess’ has
been proposed to describe this condition [3]. At present,
there is neither a laboratory test nor an imaging techni-
que able to set apart people who suffer from FM from
healthy controls. This lack of objective marker has ham-
pered FM recognition and research. A biomarker is
defined as a characteristic that can be objectively mea-
sured and evaluated as an indication of normal or
pathogenic processes or pharmacological responses to a
therapeutic intervention [4,5].
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A consistent line of research has shown that patients
who suffer from FM have signs of autonomic dysfunc-
tion, specifically signs of relentless sympathetic activity
accompanied by sympathetic hypo-reactivity to stress
[6]. It has been proposed that such autonomic dysfunc-
tion is the cause of the multiplicity of FM symptoms
and that FM is a sympathetically-maintained neuro-
pathic pain syndrome [6]. Most studies looking for auto-
nomic performance in FM have used heart rate
variability (HRV) analysis as a probing instrument.
Almost all of these HRV studies were done during day-
time. Due to the rapid advances of computer-based
science, HRV analysis is becoming a useful non-invasive
clinical tool to study autonomic nervous system
performance.
HRV analysis is based on the well-known fact that the
heart rate is not fixed, but varies from beat to beat con-
stantly. The antagonistic effects of the sympathetic and
parasympathetic branches of the autonomic nervous sys-
tem on the sinus node harmonize the periodic compo-
nents of this constant variability. Heart rate variability
can be studied in the time domain, where the basic
units are milliseconds. In the context of sinus rhythm,
more beat-to-beat variability of the heart rate signifies
more parasympathetic impulses on the sinus node. In
resting conditions, less overall HRV reflects sympathetic
predominance on the sinus node. Sympathetic predomi-
nance means either higher sympathetic activity or
decreased parasympathetic activity, or both [7]. Healthy
young individuals have ample HRV, whereas different
diseases as well as aging decrease HRV. After myocar-
dial infarction, diminished HRV is a strong predictor of
sudden death [8].
Preliminary genetic studies support FM dysautonomic
nature. Gene variations of two key sympathetic elements
have been described in this illness. FM patients have
polymorphisms associated with a defective catechol-O-
methyl- transferase (COMT) enzyme [9,10]. COMT is
involved in the inactivation of catecholamines. FM
patients also have gene variations associated with dys-
functional adrenergic receptors. These receptors modu-
late pain perception and orthostatic balance [11]. We
are not aware of epigenetic studies in FM.
Patients with FM frequently have sleeping problems
including increased awakenings and reduced slow wave
sleep. EEG evidence of disturbed sleep was the first
objective alteration found in FM [12]. The autonomic
nervous system has a direct effect on sleep architecture
[6]. Nighttime appears to be an ideal period to study
autonomic performance through HRV analysis. During
this period most people are in a stable basal supine
position. They are asleep or trying to do so.
The present study had two objectives: 1) to explore
different nocturnal HRV parameters as potential FM
biomarkers and 2) to seek correlations between such
HRV parameters and different FM symptoms, reported
in validated questionnaires related to pain, autonomic
dysfunction, fatigue, sleep, anxiety and depression.
Materials and methods
Participants
All participants were women. Eligibility criteria for
patients were the following: 1) to have FM according to
the 1990 American College of Rheumatology guidelines
[13]; 2) to be free of any medication that could affect
sleep and/or autonomic performance including tranqui-
lizers or antidepressants; 3) to be 18 to 50 years old; 4)
to be in the fertile period of their lives with active men-
strual cycles, but not to be in their menstrual period the
day of the study; 5) to have no comorbid conditions;
and 6) to freely agree to participate in the study.
Patients were sourced from different rheumatology pri-
vate practices in Mexico City.
Eligibility criteria for controls were the following: 1) to
consider themselves healthy and to have 5 or fewer FM
tender points; and 2) Not to be in their menstrual per-
iod the day of the study. For each patient, a control of
similar age (± 2 years) was recruited. Controls were
medical or paramedical personnel. A rheumatologist
examined all prospective participants to ascertain the
diagnosis of FM or the healthy status of controls. This
clinical assessment was considered the reference stan-
dard for the potential biomarker.
All participants signed a written consent form. The
study was approved by the Research and Bioethics Com-
mittee of the National Institute of Cardiology of Mexico
on August 7, 2009 (Reference number: PT-28).
Setting and data collection
The day of the study, questionnaires and other data
were prospectively collected at the Department of Elec-
tromechanical Instrumentation of the National Institute
of Cardiology in Mexico City. Then, participants were
connected to a portable Holter recorder. Twenty- four-
hour Holter recordings were done while participants fol-
lowed their routine activities during the day and while
sleeping at their homes at night. Studies were done dur-
ing working days (from Monday to Thursday),
Test methods
Symptoms evaluation
All participants filled out validated Spanish versions of
six questionnaires related to FM symptoms, autonomic
dysfunction, sleep quality, anxiety, depression, fatigue,
and general wellbeing. These six questionnaires were:
Fibromyalgia Impact Questionnaire (FIQ) [14], Medical
Outcome Sleep Scale (MOS) [15], Composite Auto-
nomic Symptoms and Signs (COMPASS) [16], Hospital
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Anxiety and Depression Scale (HADS) [17], Multidi-
mensional Assessment of Fatigue Scale (MAF) [18], and
Health Survey Short Form-36 (SF-36) [19]. FIQ is an
instrument designed to estimate the overall impact of
fibromyalgia over many dimensions (for example, func-
tion, pain level, fatigue, sleep disturbance, and psycholo-
gical distress). It is scored from 0 to 100 with the latter
number being the worst case. The average score for
patients seen in tertiary care settings is about 50. MOS
measures six dimensions of sleep; initiation, mainte-
nance, quantity, adequacy, somnolence, and respiratory
impairment. Indexes are scored on a 0-100 possible
range. Healthy people have MOS average count in the
region of 29. COMPASS explores symptoms related to
nine different autonomic function domains: orthostatic,
secretomotor, male sexual dysfunction (not used in this
study), urinary, gastrointestinal, pupillomotor, vasomo-
tor, syncope, and sleep function. COMPASS also con-
tains an understatement index and a psychosomatic
index. The worst possible overall count for women is
170. Healthy individuals have mean COMPASS scores
in the order of 10. HADS has 14 intermingled anxiety
and depression items that score from 0 to 21. A HADS
count of 11 or higher suggests the presence of a mood
disorder. MAF is a 16 item scale that measures fatigue
according to four dimensions: degree and severity, dis-
tress that it causes, timing of fatigue, and its impact on
various activities of daily living. A ‘normal’ MAF score is
about 17, the worst possible count is 50. SF-36 is a
multi-purpose, short-form health survey with 36 ques-
tions. It yields an 8-scale profile of functional health and
well-being indexes as well as psychometrically-based
physical and mental health items. In contrast to all pre-
vious questionnaires, an SF-36 higher count indicates a
better quality of life. The best possible tally is 100. A
normal SF-36 mental component count is in the region
of 50. The same normal score is also true for SF-36 phy-
sical components.
A Holter monitor (model DMS-307, DMS Inc.), was
used for electrocardiogram recording. Beat identification
and classification were performed by the automated
computer program designed for these Holter recorders
(Premier 11, Meigaoyi Inc.). Time intervals from ectopic
beats were detected and substituted by interpolated
values of normal RR intervals using an adaptive filtering
method (available on: http://tocsy.agnld.uni-potsdam.de/
) [20]. Beat-to-beat time series (HRV signal) were ana-
lyzed by a computer program produced and validated in
our technological development laboratory [21]. Readings
were done by an HRV analysis expert who was blinded
to the participant clinical status. The following time-
domain HRV parameters were analyzed: mean NN
interval (mean NN), standard deviation of the NN inter-
vals (SDNN), mean standard deviation of the average
NN intervals calculated over 5 minutes (SDANN), stan-
dard deviation of the successive NN differences (SDSD),
the square root of the mean of the sum of successive
NN differences (RMSSD), and percentage of adjacent
pairs of RR intervals that differed by more than 50 ms
from each other (pNN50). SDNN and SDANN are indi-
cative of overall HRV. SDSD, RMSSD and pNN50 evalu-
ate beat-to-beat fluctuations. Although all the indexes
are influenced by both sympathetic and parasympathetic
activity, those extracted from beat-to-beat variability are
considered good estimators of parasympathetic modula-
tion of heart rate [7,22].
All HRV parameters were defined according to inter-
national standards of measurements [8]). Calculations
were done for the entire day of the study and a sub-ana-
lysis was focused on sleeping hours (from 0000 hours to
0600 hours).
Sample size calculation
Calculation of sample size (N) was based on a previous
study from our institution [23]. In that study, the differ-
ence in mean SDANN between FM patients and con-
trols was 26 ms. The FM group’s SDANN standard
deviation was 37 ms. The control group’s SDANN stan-
dard deviation was 31 ms. Considering an alpha error =
0.05 (Za = 1.96), and beta error = 0.2 (Zb = 0.842), with
a statistical power of 80% for bilateral test, then N was
calculated as 22 subjects per group.
Statistical analysis
Clinical data are expressed as mean ± standard devia-
tion. Normal distribution was confirmed by the Kolmor-
ogv-Smirnov test. Differences between groups were
analyzed by t test or Mann-Whitney U test according to
distribution type. The best cut-off point for each para-
meter was determined from receiver-operator character-
istic (ROC) curves, according to the shortest orthogonal
distance of each curve point to the optimal point. An
example is shown in Figure 1. Sensitivity, specificity,
positive predictive value, negative predictive value and
odds ratio were estimated for each parameter. Pearson’s
or Spearman’s methods were used to search for correla-
tions between HRV parameters and the severity of fibro-
myalgia symptoms. Statistical analysis was performed
with version 16.0 of the SPSS computer program (Stat-
Soft, Inc).
Results
Patients and controls had similar demographic charac-
teristics. In contrast, sharp differences in questionnaire’s
responses were recorded (Table 1).
HRV results evaluated from the entire recording,
including those obtained during sleeping hours, are
shown in Table 2. FM patients have less variability of
heart rate than healthy controls, as evidenced by dimin-
ished SDNN pNN50 RMSSD and SDSD parameters
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evaluated from the entire recording, as well as decreased
SDNN (91.2 ms ± 21.5 versus 122.2 ms ± 32.0, P =
0.001), and SDANN (57.8 ms ± 19.2 versus 83.2 ms ±
35.9, P = 0.006) assessed during sleeping hours.
Table 3 shows the quantitative Receiver Operating
Characteristic (ROC)curve analysis of all HRV para-
meters. SDNN evaluated during sleeping hours yielded
the best performance to set apart patients from controls.
This observable fact is illustrated in Figure 2. SDNN
odds ratio was 13.6 with 95% confidence intervals ran-
ging from 3.9 to 47.8. Table 4 shows the predictive
values of HRV indexes from the entire Holter recording
and during sleeping hours (from 0000 to 0600). Noctur-
nal measurements have higher discriminating values.
SDANN has the highest specificity (82) and highest
positive predictive value (79) for FM diagnosis.
There were multiple statistically significant associa-
tions between nocturnal HRV parameters and diverse
FM symptoms. Table 5 displays only those significant
correlations having an absolute r value ≥ 0.5. In the FM
group, there is a correlation between HRV parameters
indicative of sympathetic predominance and the severity
of pain, constipation, and depression. In contrast,
healthy controls display an opposite behavior. They have
positive correlations between HRV markers indicative of
parasympathetic predominance (either reduced sympa-
thetic activity, increased vagal activity, or both) with the
total FIQ score and the severity of fatigue, anxiety, and
depression. Figure 3 shows a scatter gram of total FIQ
scores and SDNN indexes in healthy controls during
sleeping hours.
Discussion
The intense search for a valid FM biomarker has so far
yielded unsatisfactory results. Dynamic neuroimaging
techniques are able to distinguish FM patients from
healthy controls [24] but these are expensive procedures
and their distinctive features are not found in resting
states but rather as a result of pain induction. HRV ana-
lysis is an economical non-invasive technique. Previous
HRV studies in FM disclosed changes consistent with
sympathetic predominance (summarized in [6]). Most
studies were done during activity hours. We were able
to find only one prior time-domain HRV investigation
in FM focusing on nighttime measurements. Chervin et
al. studied 13 patients with FM and 11 controls in a
sleep laboratory. Similar to our results they found
decreased nighttime SDANN in patients [25].
Figure 1 Receiver-operator characteristics (ROC) curves (A) and scatter gram (B) of the nocturnal heart rate variability parameter
SDNN, evaluated from Holter recording of 22 female patients with fibromyalgia and 22 matched healthy controls. The best cut-off
point (indicated by symbol ‘x’ in Figure 1-A was determined according to the shortest orthogonal distance from each point to the optimum
value (0,1). The line in figure 1-B indicates the cut-off point (114 milliseconds (ms). SDNN, standard deviation of the NN intervals.
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In the present investigation, nocturnal HRV para-
meters indicative of ongoing sympathetic predominance
were able to clearly set apart FM patients from normal
controls. It seems important to reiterate that sympa-
thetic predominance means either higher sympathetic
activity or decreased parasympathetic activity, or both.
In the patient group HRV parameters suggestive of
decreased parasympathetic activity correlated with dif-
ferent FM symptoms, including its main complaint: pain
intensity.
HRV recording length strongly affects SDNN and
SDANN. This is one reason why we did a fixed 00.00
hour to 06.00 hour sub-analysis. From the Holter tra-
cings, we determined that participants were in bed dur-
ing this part of the study. We did not perform a
polysomnographic study, so we are not able to indicate
if participants were asleep during this nighttime period.
There is an intimate relationship between autonomic
performance and sleep. The HRV alterations found in
FM patients probably reflect the lack of sustained deep
restful sleep. However, the cause - effect connection of
sleep, pain and autonomic dysfunction in FM needs
further characterization.
Our study has several peculiarities: it was done in
women while sleeping in the familiar environment of
their homes rather than in a sleep laboratory. This
home-based night-time appraisal allowed us to study
individuals in a stable habitual basal situation in which
most people are (or attempt to be) resting. None of the
participants was on any medication that could alter
autonomic activity. For this pilot study, we focused on
women in the fertile period of their lives in order to
avoid menopausal dysautonomic confounding variables.
Patients were sourced from several private rheumatol-
ogy clinics in Mexico City. As a group they were lean
(mean body mass index = 24.6 kg/m2) and greatly
impacted by the FM (FIQ’s mean value = 64 units).
These characteristics probably do not apply to the FM
Table 1 Demographic features and symptom scores in






Age (years) 32.4 ± 7.9 30.4 ± 7.4 0.406
Body mass index (kg/m2) 24.6 ± 4.4 25.0 ± 3.2 0.719
Disease duration (years) 6.8 ± 6.1 N/A N/A
Total FIQ score 64.8 ± 14.1 12.0 ± 10.7 < 0.0001
VAS disability 6.5 ± 2.3 0.5 ± 1.1 < 0.0001
VAS pain 7.2 ± 2.2 0.7 ± 1.5 < 0.0001
VAS fatigue 8.3 ± 1.4 1.8 ± 2.2 < 0.0001
VAS sleep 7.3 ± 3.1 2.1 ± 2.4 < 0.0001
VAS morning stiffness 7.2 ± 2.5 0.7 ± 1.4 < 0.0001
VAS anxiety 7.3 ± 2.4 2.1 ± 2.3 < 0.0001
VAS depression 6.3 ± 3.1 1.8 ± 2.5 < 0.0001
Total COMPASS score 53.6 ± 18.2 13.5 ± 10.6 < 0.0001
Orthostatic intolerance 20.4 ± 9.6 5.2 ± 5.8 < 0.0001
Vasomotor domain 3.3 ± 2.9 0.4 ± 1.1 < 0.0001
Secretomotor 4.7 ± 3.6 1.0 ± 1.5 < 0.0001
Gastroparesis 2.9 ± 1.5 0.5 ± 0.7 < 0.0001
Diarrhea 7.4 ± 5.4 2.5 ± 3.1 0.001
Constipation 4.4 ± 2.4 1.1 ± 1.2 < 0.0001
Bladder 4.0 ± 4.7 1.0 ± 1.6 0.010
Pupillomotor 2.8 ± 1.2 0.7 ± 1.1 < 0.0001
Sleep 2.8 ± 1.7 0.5 ± 0.8 < 0.0001
Syncope 0.5 ± 1.4 0.1 ± 0.8 0.305
Understatement index 0.8 ± 1.3 3.0 ± 2.9 0.003
Psychosomatic index 1.2 ± 1.5 0.2 ± 0.6 0.004
MAF 40.3 ± 5.5 15.6 ± 11.3 < 0.0001
MOS 60.5 ± 11.2 19.2 ± 10.4 < 0.0001
SF-36 mental component 38.9 ± 5.3 42.2 ± 5.2 0.043
SF-36 physical component 53.0 ± 7.6 63.0 ± 83 < 0.0001
HADS depression 7.3 ± 3.0 3.9 ± 4.4 0.005
HADS anxiety 12.3 ± 4.0 5.5 ± 2.9 < 0.0001
COMPASS, composite autonomic symptom scale; FIQ, fibromyalgia impact
questionnaire; HADS, hospital anxiety and depression scale; MAF,
multidimensional assessment of fatigue; MOS, medical outcome sleep scale;
SF-36, short form 36 items health survey; VAS, visual analogue scale. N/A =
not applicable.






Mean NN (ms) 758.4 ± 70.9 796.5 ± 92.0 0.132 881.5 ± 94.8 915.6 ± 122.9 0.310
SDNN (ms) 133.7 ± 28.7 152.6 ± 32.8 0.047 91.2 ± 21.5 122.2 ± 32.0 0.001
SDANN (ms) 120.0 ± 28.1 132.5 ± 27.9 0.144 57.8 ± 19.2 83.2 ± 35.9 0.006
SDSD (ms) 36.0 ± 13.9 47.3 ± 16.9 0.020 45.9 ± 19.6 56.9 ± 21.3 0.084
RMSSD (ms) 36.0 ± 13.9 47.3 ± 16.9 0.020 45.9 ± 19.6 56.9 ± 21.3 0.084
pNN50 (%) 13.6 ± 10.3 20.5 ± 11.6 0.045 23.9 ± 17.5 31.4 ± 17.5 0.160
Holter recordings were analyzed for 24 hours, and during sleeping time (from 00.00 to 06.00 hours). Results are shown as mean ± standard deviation. Student’s t
test calculated the differences between fibromyalgia group and control group. Mean NN, mean NN interval; ms, milliseconds; pNN50, percentage of adjacent
pairs of R-R intervals that differ by more than 50 ms from each other in a given time period; RMSSD, Square root of the mean of the squares of differences
between adjacent NN intervals; SDANN, mean standard deviation of the average NN intervals calculated over 5 minutes; SDNN, standard deviation of the NN
intervals; SDSD, standard deviation of the successive NN differences;
Lerma et al. Arthritis Research & Therapy 2011, 13:R185
http://arthritis-research.com/content/13/6/R185
Page 5 of 9
Table 3 Receiver-operator characteristic curve analysis of heart rate variability indexes
AUC (95% CI) P-valuea Best cut-off value Distance to optimum value (0,1)
24-hour
Mean NN (ms) 0.61 (0.45 - 0.79) 0.18 779 0.53
SDNN (ms) 0.67 (0.50 - 0.83) 0.05 141 0.45
SDANN (ms) 0.64 (0.48 - 0.81) 0.11 119 0.48
SDSD (ms) 0.69 (0.53 - 0.84) 0.03 40 0.48
RMSSD (ms) 0.69 (0.53 - 0.84) 0.03 40 0.48
pNN50 (%) 0.68 (0.52 - 0.83) 0.04 13 0.53
Sleeping hours
Mean NN (ms) 0.59 (0.41 - 0.77) 0.30 922 0.49
SDNN (ms) 0.79 (0.66 - 0.92) 0.00 114 0.35
SDANN (ms) 0.75 (0.60 - 0.897) 0.00 59 0.37
SDSD (ms) 0.64 (0.48 - 0.81) 0.09 44 0.53
RMSSD (ms) 0.64 (0.48 - 0.81) 0.09 44 0.53
pNN50 (%) 0.63 (0.47 - 0.80) 0.13 31 0.55
aNull hypothesis is that area under the curve = 0.5.
Holter recordings were analyzed for 24 hours, and during sleeping time (from 00.00 to 06.00 hours). AUC, area under the curve; CI, confidence interval; Mean NN,
mean NN interval; SDNN, standard deviation of the NN intervals; SDANN, mean standard deviation of the average NN intervals calculated over 5 minutes; ms,
milliseconds; SDSD, standard deviation of the successive NN differences; RMSSD, square root of the mean of the squares of differences between adjacent NN
intervals; pNN50, percentage of adjacent pairs of R-R intervals that differ by more than 50 ms from each other in a given time period.
Figure 2 Odds ratio of heart rate variability parameters evaluated from Holter recordings of 22 female patients with fibromyalgia and
22 matched healthy controls. The cut-off points selected for each parameter are shown in Table 3. Data are presented as odds ratio (95%
confidence interval)
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population at large. It should be noted however, that
controls had a similar age and a similar body mass
index. Our database did not register variables that may
affect HRV such as level of physical activity or use of
oral contraceptives. It remains to be established if the
HRV differences found in this study persist in obese
post-menopausal women, in men or in patients with
other painful rheumatic syndromes such as rheumatoid
arthritis. In this regard, it is worth noting that a pre-
vious study revealed that FM patients have significantly
more autonomic symptoms (including sleeping pro-
blems) than patients with rheumatoid arthritis [26].
Even so, a pending issue is to directly compare night-
time HRV parameters in FM versus other painful rheu-
matic syndromes.
Another novel finding of our study is the correlation
between several nighttime HRV parameters indicative of
sympathetic predominance and different FM symptoms,
including pain severity. This correlation, observed in
patients, does not define the cause-effect direction.
Nevertheless, previous findings suggest that FM could
be a sympathetically-maintained pain syndrome: patients
who suffer from FM have norepinephrine-evoked pain
[27], as well as COMT gene polymorphisms associated
with a defective catecholamine clearing enzyme [9,10].
This body of evidence suggests that sympathetic hyper-
activity could be the cause of FM symptoms.
An unexpected result of our study was the reverse
correlation between HRV parameters and FM symptoms
seen in healthy controls when compared to patients. We
anticipated that there would be a continuum between
HRV values and FM symptoms across these two groups.
However, contrary to what is seen in patients, in healthy
individuals, HRV markers suggestive of parasympathetic
predominance have a positive correlation with some FM
symptoms and with total FIQ scores. The reason for
this surprising dichotomy is not clear. It could be specu-
lated that healthy individuals have low basal sympathetic
tone. For them, the feeling of fatigue or depression may
be due to lack of sympathetic drive. In contrast, indivi-
duals with FM have higher basal sympathetic tone. The
system is already overworked and exhausted. Further
sympathetic activity is unable to overcome fatigue. In
favor of this notion are different studies showing that in
contrast to what is seen in healthy individuals, FM
patients have blunted sympathetic responses to different
types of stressors [6]. Another possible explanation for
this dichotomy is that healthy individuals have harmo-
nious circadian rhythms; thus, fatigue during the day is
followed by a restful night.
Table 4 Predictive value of heart rate variability indexes










Mean NN ≤ 779 ms 73 55 62 67
SDNN ≤ 141 ms 68 68 68 68
SDANN ≤ 119 ms 64 68 67 65
SDSD ≤ 40 ms 64 68 67 65
RMSSD ≤ 40 ms 64 68 67 65
pNN50 ≤ 13% 55 73 67 62
Sleeping hours
Mean NN ≤ 922 ms 73 59 64 68
SDNN ≤ 114 ms 86 68 73 83
SDANN ≤ 59 ms 68 82 79 72
SDSD ≤ 44 ms 55 73 67 62
RMSSD ≤ 44 ms 55 73 67 62
pNN50 ≤ 31% 68 55 60 63
Mean NN, mean NN interval; pNN50, percentage of adjacent pairs of R-R
intervals that differ by more than 50 ms from each other in a given time
period; ms, milliseconds; RMSSD, square root of the mean of the squares of
differences between adjacent NN intervals; SDANN, mean standard deviation
of the average NN intervals calculated over 5 minutes; SDNN, standard
deviation of the NN intervals; SDSD, standard deviation of the successive NN
differences.
Table 5 Significant correlations with r absolute value ≥
0.05 between symptom scales and HRV parameters









FIQ total score SDNN 0.69 <
0.001
SDANN 0.60 0.003
FIQ VAS pain SDSD -0.65 0.001
RMSSD -0.65 0.001
pNN50 -0.62 0.002
FIQ VAS fatigue SDNN 0.65 0.001
SDANN 0.57 0.005
FIQ VAS anxiety SDNN 0.62 0.002
SDANN 0.53 0.011
FIQ VAS depression SDNN 0.52 0.012
SDANN 0.51 0.015













COMPASS, composite autonomic symptom scale; HADS, hospital anxiety and
depression scale; FIQ, fibromyalgia impact questionnaire; Mean NN, mean NN
interval; pNN50, percentage of adjacent pairs of R-R intervals that differ by
more than 50 ms from each other in a given time period; RMSSD, square root
of the mean of the squares of differences between adjacent NN intervals;
SDANN, mean standard deviation of the average NN intervals calculated over
5 minutes; SDNN, standard deviation of the NN intervals; SDSD, standard
deviation of the successive NN differences; SF-36, health survey short format
36 items; VAS, visual analogue scale.
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Our results contradict the suggestion that FM is just
one end of a continuous spectrum of ‘normal’ symp-
toms, including pain and fatigue [2,3]. Severe symptoms
seen in patients have opposite autonomic correlations
when compared to mild symptoms seen in healthy peo-
ple. Based on previous studies from our institution [6],
we propose that FM is a sympathetically-maintained
neuropathic pain syndrome. Hypothetically, ongoing
sympathetic hyperactivity, trauma, or infection could
induce abnormal connections between the sympathetic
nervous system and the nociceptive systems. These
short-circuits may take place in the paravertebral
nodules called dorsal root ganglia. Altered sodium chan-
nels may facilitate this pain sensitization. Sympathetic
dysfunction can also explain non-pain related FM symp-
toms [28].
HRV analysis is a computer-based technology, there-
fore, it has abundant development potentials. Theoreti-
cally, the combined computerized nocturnal
measurements of autonomic dependent vital sign vari-
ables, such as blood pressure, heart rate, and respiration,
may yield even more discriminative values for FM.
Because HRV analysis is a non-invasive technique, it
may become a useful objective tool to estimate FM
severity and/or responses to therapies.
Conclusions
Nocturnal HRV parameters indicative of sympathetic
predominance are significantly different in FM patients
when compared to healthy individuals. In FM patients,
there is a correlation between these HRV indices and
several FM symptoms, including pain severity. Healthy
controls display an opposite behavior. These results
reinforce existing evidence suggesting that sympathetic
hyperactivity could be the cause of FM symptoms. HRV
parameters are potential FM biomarkers.
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